Foxtale Evolves Into a House of Brands; Introduces Hula Hoop by Foxtale, Following 700-Crore Topline GMV Milestone
The new science-driven bodycare brand strengthens Foxtale's evolution into a category-defining House…
Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in…
Milliken & Company Launches Millad ClearX 9000: The Clear Choice for Polypropylene
Delivers exceptional clarity with lower additive levels, streamlining production and expanding formulation…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence…